severe sepsis or septic shock
Conditions
Interventions
placebo group:normal saline with 1% human serum albumin
Sponsors
Cell Biotherapy Center, Daping Hospital, Third Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Good adherence to patients and their families with informed consents; 2. patients of ICU, aged from 16 to 65 years old; 3. Have a clear diagnosis of severe sepsis and septic shock; 4. Expected survival time longer than 28 days.
Exclusion criteria
Exclusion criteria: 1. Patients with uncorrected disease, such as advanced cancer or other terminal illness, the prospective survival period less than 28 days; 2. Patients in the foreseeable dying state; 3. HIV infected with CD4 less than 50/mm3; 4. Have the bone marrow, lungs, liver, pancreas, or history of small bowel transplantation; 5. Chronic renal failure need hemodialysis or peritoneal dialysis; 6. Known or potential of portal hypertension, chronic icteric, chronic liver cirrhosis and ascites; 7. Acute pancreatitis with no clear focal infection; 8. Patient participating or having participated in a clinical trial with another investigational drug Within 30 days before the start of this clinical trial; 9. Patient is pregnant or nursing; 10. Fungal sepsis; 11. History of patient is allergic to biological products, allergic reactions or other serious reaction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-Day All-Cause Mortality; | — |
Countries
China
Contacts
Public ContactXiang Xu
Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing
Outcome results
None listed